Clinical trials: Nosocomial Pneumonia
Pneumonia, Ventilator Associated Pneumonia
Safety and Pharmacokinetics of KBPA-101 in Hospital Acquired Pneumonia Caused by O11 Pseudomonas Aeruginosa
The objectives of this open study are to assess the safety, tolerability, pharmacokinetics and clinical outcome of patients who have HAP caused by Pseudomonas aeruginosa serotype O11 after three separate administrations of…
- Trial name
- NCT00851435
- Testing
- KBPA-101
- Where
- Switzerland
- Volunteers
- 15 people
- Sponsor
- Kenta Biotech Ltd
VAP - Ventilator Associated Pneumonia
Early Identification of Pathogens in Children With Respiratory Tract Infection by Mechanical Ventilation Using mNGS
VAP（Ventilator-associated pneumonia）is the most common complication of mechanical ventilation in severely ill patients. VAP is defined as pneumonia occurring 48 hours after patients receive mechanical ventilation, including…
- Trial name
- NCT04955821
- Testing
- mNGS diagnose of VAP
- Volunteers
- 400 people
- Sponsor
- Children's Hospital of Fudan University
Ventilator Associated Pneumonia
Antibiotic Therapy Practices for Ventilator-Associated Pneumonia (PETUNIA)
The French Society of Intensive Care conducts a comprehensive assessment of current antibiotic therapy practices in critically ill patients suspected of Ventilator-Associated Pneumonia (VAP).
- Trial name
- PETUNIA (NCT06243094)
- Testing
- Antibiotic
- Where
- France
- Volunteers
- 1,060 people
- Sponsor
- French Society for Intensive Care
Ventilated Patient in Intensive Care
Variation in Viscoelastic Properties of Pulmonary Mucus in Patients Undergoing Mechanical Ventilation
Ventilator-associated pneumonia (VAP) is defined as an infection of the lung parenchyma in patients undergoing invasive mechanical ventilation for at least 48 hours.
- Trial name
- RHEOREA (NCT07490028)
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Centre Hospitalier Intercommunal Aix-Pertuis
Ventilator Associated Pneumonia, Lower Respiratory Infection
Pharmacokinetics, Safety and Efficacy of POL7080 in Patients With Ventilator Associated Pseudomonas Aeruginosa Pneumonia
To investigate the pharmacokinetic characteristics of POL7080 co-administered with SoC during 10 to 14 days of treatment in VAP patients due to suspected or documented Pseudomonas aeruginosa infection
- Trial name
- NCT02096328
- Testing
- POL7080
- Where
- 10 sites in Greece, Spain
- Volunteers
- 25 people
- Sponsor
- Polyphor Ltd.
Pneumonia
Improving Oral Care to Reduce Hospital-Acquired Pneumonia (HAP) in the Acute Neurologically Impaired Adult
Hypothesis: The investigators hypothesize that the current oral protocol is sub-optimal and an enhanced protocol will decrease the incidence of hospital acquired pneumonia (HAP)in the acute, non-intubated, care-dependent…
- Trial name
- NCT01498601
- Testing
- Enhanced oral care protocol
- Where
- Canada
- Volunteers
- 32 people
- Sponsor
- Fraser Health
Nosocomial Infections
Nosocomial Respiratory Virus Infection
Hospital-acquired Viral Respiratory Infections (HAVRI) are associated with substantial burden on health care systems. The prevention and control of these viral infections rely on multiple measures such as hand hygiene or wearing…
- Trial name
- NOSOVIRUS (NCT06643039)
- Testing
- Nasopharyngeal swab, Questionnaire
- Where
- 6 sites in France
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Ventilator-Associated Pneumonia (VAP)
Immediate Versus Substantiated Antibiotic Therapy in Suspected Non-Severe Ventilator-Associated Pneumonia
Ventilator-associated pneumonia is the leading nosocomial infection in the intensive care units, and is associated with prolonged mechanical ventilation and overuse of antibiotics.
- Trial name
- POSTPONE (NCT06743529)
- Testing
- control group, Conservative strategy
- Where
- 42 sites in France, Guadeloupe
- Volunteers
- 686 people
- Sponsor
- Nantes University Hospital
Antimicrobial Resistance (AMR)
NCCR AntiResist:: New Approaches to Combat Antibiotic-resistant Bacteria
This is an explorative, mono-center study including prospectively collected patient samples from the University Hospital of Basel.
- Trial name
- AntiResist (NCT05017766)
- Testing
- analysis of antimicrobial resistance
- Where
- Switzerland
- Volunteers
- 8,000 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Pneumonia
A Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics/Pharmacodynamics of BAYQ3939 in Patients With Bacterial Pneumonia
The main objective of this study is to investigate the safety, pharmacokinetics (PK) and the relationship between PK and pharmacodynamics (Minimum Inhibitory Concentration [MIC] and Mutant Prevention Concentration [MPC]) of…
- Trial name
- NCT01561794
- Testing
- Ciprofloxacin (Cipro, BAYQ3939)
- Where
- 20 sites in Japan
- Volunteers
- 44 people
- Sponsor
- Bayer
Healthcare-associated Pneumonia (HCAP), Bloodstream Infections (BSI)
Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
This study is designed to provide evidence of efficacy of cefiderocol in the treatment of serious infections in adult patients caused by carbapenem-resistant Gram-negative pathogens.
- Conditions
- Healthcare-associated Pneumonia (HCAP), Bloodstream Infections (BSI), Hospital Acquired Pneumonia (HAP), Complicated Urinary Tract Infection (cUTI)
- Trial name
- CREDIBLE - CR (NCT02714595)
- Testing
- Cefiderocol, Best Available Therapy
- Where
- 85 sites in United States, Brazil and 14 more
- Volunteers
- 152 people
- Sponsor
- Shionogi
Pneumonia
Probiotic Enteral Administration in Mechanically Ventilated Patients
The objective of this study is to assess the effects of a daily enteral supplementation with probiotics within a population of critically ill, mechanically ventilated patients.
- Trial name
- NCT00122408
- Testing
- Ergyphilus
- Where
- 3 sites in France
- Volunteers
- 740 people
- Sponsor
- Central Hospital, Nancy, France
SARS-CoV2 Infection, Ventilator Associated Pneumonia
Ventilation Associated Pneumonia and Covid-19
In December 2019, a new pandemic emerged, the COVID-19 disease caused by a SARS-Cov-2 virus. One of the most common symptoms of COVID-19 is mainly respiratory failure and patients requires assistance by mechanical ventilation.
- Conditions
- SARS-CoV2 Infection, Ventilator Associated Pneumonia, Ards, COVID-19
- Trial name
- ECOLCOVID (NCT05089968)
- Where
- France
- Volunteers
- 268 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Hospital-acquired Pneumonia, Healthcare Associated Infection
Modular Prevention Bundle for Non-ventilator-associated Hospital-acquired Pneumonia (nvHAP)
Background: Hospital acquired pneumonia (HAP) is divided in two distinct groups, ventilator-associated pneumonia (VAP) and non-ventilator-associated HAP (nvHAP).
- Conditions
- Hospital-acquired Pneumonia, Healthcare Associated Infection, Infection Prevention
- Trial name
- NCT03361085
- Testing
- nvHAP Prevention Bundle
- Where
- Switzerland
- Volunteers
- 45,000 people
- Sponsor
- University of Zurich
Community Acquired Pneumonia, Hospital Acquired Pneumonia
HOME FIRST Pilot: a Study of Early Supported Discharge in Patients With Lower Respiratory Tract Infections
HOME FIRST (Home Followed - up with Infection Respiratory Support Team) is an early supported discharge scheme. It will enable patients with lower respiratory tract infection (LRTI) to be provided with high quality safe…
- Conditions
- Community Acquired Pneumonia, Hospital Acquired Pneumonia, Lower Respiratory Tract Infection
- Trial name
- HOMEFIRST (NCT02454114)
- Testing
- HOMEFIRST, Standard Hospital Care
- Where
- United Kingdom
- Volunteers
- 26 people
- Sponsor
- Liverpool University Hospitals NHS Foundation Trust
Ventilator Associated Pneumonia, Corona Virus Infection
Epidemiology and Outcome of Ventilator-associated Pneumonia Among Critically Ill COVID-19 Patients
The aim of this study is to determine the risk factors for development of ventilator-associated pneumonia (VAP) and to identify the prognostic factors of VAP among Coronavirus Disease 2019 (CoViD-19) patients.
- Trial name
- NCT04372576
- Testing
- Assessment of ventilator-associated pneumonia criteria
- Where
- Hungary
- Volunteers
- 30 people
- Sponsor
- Semmelweis University